Literature DB >> 15056977

Thalidomide as a nitric oxide synthase inhibitor and its structural development.

Rumiko Shimazawa1, Hiroko Sano, Aya Tanatani, Hiroyuki Miyachi, Yuichi Hashimoto.   

Abstract

Thalidomide has been found to exhibit weak nitric oxide synthase (NOS)-inhibitory activity. Structural development studies of thalidomide showed that some N-2,6-dimethylphenylhomophthalimide analogs possess NOS-inhibiting activity.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15056977     DOI： 10.1248/cpb.52.498

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN： 0009-2363            Impact factor:   1.645


  4 in total

1.  Thalidomide ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in an experimental model.

Authors:  Keyvan Amirshahrokhi; Ali-Reza Khalili
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

2.  In vitro anticancer property of a novel thalidomide analogue through inhibition of NF-kappaB activation in HL-60 cells.

Authors:  Min Li; Wan Sun; Ya-ping Yang; Bo Xu; Wen-yuan Yi; Yan-xia Ma; Zhong-jun Li; Jing-rong Cui
Journal:  Acta Pharmacol Sin       Date:  2008-12-22       Impact factor: 6.150

3.  Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells.

Authors:  K P Tamilarasan; Gopi Krishna Kolluru; Megha Rajaram; M Indhumathy; R Saranya; Suvro Chatterjee
Journal:  BMC Cell Biol       Date:  2006-04-04       Impact factor: 4.241

4.  Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.

Authors:  Kunkun Han; Xin Xu; Guodong Chen; Yuanying Zeng; Jingyu Zhu; Xiaolin Du; Zubin Zhang; Biyin Cao; Zhaopeng Liu; Xinliang Mao
Journal:  J Hematol Oncol       Date:  2014-01-15       Impact factor: 17.388
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.